摘要
目的研究和评价单药泰素帝周方案治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法对2000年10月～2004年2月我科收治的51例年龄在65～81岁的老年晚期NSCLC患者应用单药泰素帝周方案化疗,剂量35mg(m2/周),连用3周,休息1周重复,治疗有效者最多接受16周治疗或至疾病进展。结果51例患者共接受441周的泰素帝化疗,近期有效17例,有效率33.3%;稳定20例,占39.2%。1年生存率35.3%,2年生存率9.8%。Ⅲ/Ⅳ度白细胞下降10%,Ⅲ度贫血2%,非血液学毒性反应也较轻微,可以耐受。结论单药泰素帝周方案治疗晚期老年人NSCLC耐受性良好,可使老年患者的症状改善,生存期延长,安全有效。
Objective To study the clinical effectiveness and toxicities of weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma.Methods From October 2000 to February 2004,51 cases of elderly patients, aged from 65 years to 81 years, with advanced nonsmall cell lung carcinoma were received docetaxel,35mg/m^2,administercd weekly for 3 consecutive weeks,followed by 1 week without trcatment.Responding patients continued weekly docetaxel for a maximum of 16 weeks or until dis- ease progression.Results Total 441 weeks chemotherapy were received,the response rate was 33.3 percent （17/51）,stable disease （SD） rate was 39.2 （20/51）.The 1-year and 2-years survival rate were 35.3 percent and 9.8 percent respectively.Grade 3/4 leukopenia was noted in 5 patients（10%）,and grade 3 anemia was noted in only 1 patient（2%）.Nonhematologic toxicities were mild also and could well tolerated.Conclusion Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma can improve symptom, prolong survival time, and can be well tolerated.
出处
《江西医药》
CAS
2008年第1期6-8,共3页
Jiangxi Medical Journal
关键词
老年人
非小细胞肺癌
化疗
泰素帝
the elderly
nonsmall cell lung carcinoma
chemotherapy
docetaxel
